US labelling update for 'Zetia'

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2003年 / 959卷 / 1期

关键词：

Public Health; Clinical Trial; Adverse Reaction; Myopathy; Safety Profile;

D O I：

10.2165/00128415-200309590-00003

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[21] Mesoridazine labelling changed in the US
Reactions Weekly, 2000, 824 (1) : 3 - 3
[22] US Erbitux labelling updated
Reactions Weekly, 2005, 1070 (1) : 2 - 2
[23] Labelling changes for `Lariam' in the US
Reactions Weekly, 2002, 923 (1) : 2 - 2
[24] Alosetron labelling revised in the US
Reactions Weekly, 2000, 817 (1) : 2 - 2
[25] Irinotecan labelling updated in the US
Reactions Weekly, 2002, 910 (1) : 2 - 2
[26] Labelling changes for pramipexole in the US
Reactions Weekly, 1999, 771 (1) : 2 - 2
[27] Zetia mechanism of action.
Altmann, SW
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U935 - U936
[28] Zetia's Miraculous Popularity
Herper, Matthew
FORBES, 2009, 184 (11): : 56 - 56
[29] Labelling update for infliximab warns of risk of infections
Reactions Weekly, 2001, 876 (1) : 2 - 2
[30] Exubera labelling update regarding lung cancer
Reactions Weekly, 2008, 1198 (1) : 3 - 3

← 1 2 3 4 5 →